Mind Medicine Australia’s Progress and Achievements Since 2019
Mind Medicine Australia’s key accomplishments in recent years
In our first three and a half years, we have made remarkable progress in growing public awareness of Psychedelic-Assisted Therapy in Australia. We are seeing a paradigm shift in the curiosity, acceptance, and interest in the use of psilocybin and MDMA-assisted therapy for depression, addiction, PTSD, obsessive-compulsive disorder, anorexia, cognitive decline, end-of-life stress, and other mental and physical illnesses in our communities.
Our goal is to build the ecosystem for these treatments in Australia and ensure they are accessible to all who need them in medically controlled environments. Please see our key strategic objectives below.
What we have achieved in three and half years with your support:
Awareness and Knowledge Building
• 200+ webinars, screenings and special events attracting 41,000+ participants
• Launch of free online Global Webinar Series where World-leading experts provide illuminating presentations and conversations about the ground-breaking opportunity psychedelic-assisted therapies offer.
• Launch of Mind Medicine Australia Podcast series
• Over 550,000 visits to the Mind Medicine Australia website
• Over 39,000+ followers on our social media channels
• Over 500,000+ views on our YouTube Channel
• 6000+ visits to our e-book about psychedelic-assisted psychotherapies
• Over 35,000+ people in our database incl. over 15,000 health professionals and over 1000 psychiatrists
• 500+ regular donors
• 200+ media appearances
• 33+ local Chapters around Australia and New Zealand with 2200+ members and growing
• 55,000+ views to our TGA How-to guide during the 2022 public submission period
• Video animation explaining the mental illness epidemic in Australia and the benefits of psilocybin and MDMA-assisted psychotherapy with 80,000+ views
• Created a short documentary, Science vs Stigma, to dispel some of the myths associated with these important medicines with over 28,000+ views
• Over 150,000+ views of Shroom Boom, a light-hearted music video
• Implemented a Board Observership program in conjunction with VMIAC.
• Appointed as member of peak body, Mental Health Australia
• Launch of MMA online shop selling a range of unique merchandise including Australia’s first book of Psychedelic Healing Stories
• Initiated Australia’s first Essential Research poll to gauge the sentiment of the Australian public on the issue of access to psychedelic medicines in medically controlled environments as treatments for key classes of mental illness. 67% agreed that ‘People experiencing terminal illness should have the choice to use psychedelic-assisted therapy to ease end of life distress’.
• Presented and produced Mind Medicine Australia’s inaugural International Summit on Psychedelic Therapies for Mental Illness in November 2021
• Nearly 1000 people registered for our two-day workshop and Global Summit from every state of Australia and more than 15 other nations
• Over 90,000 views of our Summit sizzle reel
• Over 80,000 visits to the Summit website
• Over 5000 queries received from the Summit website
• 110 virtual breakout rooms
• 32 global leaders in the field presented on a range of topics
• 19 major Corporate partners
• Over 160 Education partners
• 17 Supplier Partners
• 15 Media Partners
• 8 Scholarship winners
• 5 Poster winners
• 1 global 4-day event with massive impact
Access to Medically Approved Therapy
• Further submissions made to the TGA to reschedule MDMA and psilocybin from Schedule 9 (Prohibited Substances) to Schedule 8 (Controlled Medicines)
• Australia’s TGA has granted approvals through SAS-B for psilocybin and MDMA assisted therapies for patients on a case-by-case basis
• Continued review and lobbying of Federal and State legislative and regulatory requirements to permit the medicines for clinical use to treatment resistant patients
• Granted an Innovation Patent over an improved method of synthesis of MDMA
• Successfully procured medical grade GMP standard psychedelic medicines for import to Australia for use in trials
• Developing a gold standard National Care Program, clinical protocols and standard operating practices for psychedelic-assisted therapies in partnership with leading clinical groups around Australia
• Key university student placement partnerships with University of Melbourne
Professional Development Program
• Our highly anticipated Certificate in Psychedelic-Assisted Therapies commenced in January 2021 featuring a world class Faculty. We have been thrilled to welcome 260 therapists including GPs, physicians, psychiatrists, psychologists, psychotherapists, mental health nurses, social workers, occupational therapists, addiction specialists, paramedics and counsellors.
• Confirmed world-leading facilitators for our Certificate in Psychedelic-Assisted Therapies (CPAT) professional development course
• Described as “the best course of its kind in the world” by Prof. David Nutt on ABC Radio National interview (UK)
• Over 500+ applications received since launch
• Over $200,000 raised for CPAT grants through philanthropy to support those in regional and rural areas and therapists suffering financial hardship. Over 50 grants have been awarded so far.
• Over 127,000+ views of the CPAT sizzle reel
• Mind Medicine Institute (MMI) established to further develop educational and training courses
• Launch of the Fundamentals in Psychedelic-Assisted Therapies Course with over 320+ participants so far
- Recognition by key peak/membership bodies of our professional development and training programs
Engagement with University Sector and Novel Research
- Successfully advocated for $15 million to support innovative mental health clinical trials utilising psychedelic-assisted therapies from the Federal Government through the Medical Research Futures Fund
• Launch of The Monash University Neuromedicines Discovery Centre, initially proposed by MMA and developed over a 2-year period
• 17+ current trials of psilocybin, MDMA, LSD and Ibogaine in Australia and New Zealand.
• Developed a BLOG, significant education resources and partnered with Universities to disseminate these as well as sharing these via our website
• Discussions with key University stakeholders continue
Noteworthy from Media Releases:
- TGA Expert Review Findings Support the Therapeutic Use of Medicinal Psychedelics in Treating Mental Health Crisis in October 2021
- Mind Medicine Institute Launched as a Dedicated Training, Education and Clinical Services Organisation Focusing on Psychedelic Assisted Therapies for Mental Illness and the Developing Understanding of the Mind, Cognition and Human Consciousness in October
- Mind Medicine Australia Launched Australia’s First Book of Psychedelic Healing Stories in October 2021
- Monash University announced the establishment of the Neuromedicines Discovery Centre to Focus on Psychedelic-Assisted Therapies for the Treatment of Key Classes of Mental Illness in November 2021
- Mind Medicine Australia hosted Australia’s Inaugural International Summit on Psychedelic Therapies for Mental Illness online in November 2021
- Mind Medicine Australia joined a global coalition launched to secure a rescheduling of psilocybin under the 1971 UN Convention on Psychotropic Substances in January 2022
- New Polling by Mind Medicine Australia Revealed Over 60% of Australians Support Increased Access to Psychedelic Medicines in February 2022
- Mind Medicine Australia Lodged New Applications for the Restricted Medical use of MDMA and Psilocybin Assisted Therapies for Patients with Treatment Resistant Mental Illnesses in March 2022 The full applications can be found here.
The progress we are making in public education was exemplified in several headline media articles including in the Australian Financial Review, The Australian, The Age, Herald Sun, The Saturday Paper and Vogue Australia and media interviews including with Channel Nine, Channel 10, The Project, ABC and numerous other TV and radio stations and online media.
Our primary focus over the next couple of years will be on psilocybin-assisted psychotherapy and MDMA-assisted psychotherapy, given their “Breakthrough Therapy Designation” with the Food and Drug Administration (“FDA”) in the United States and the strong clinical evidence that supports both their effectiveness and safety. We are also interested in developing other medicines to treat a variety of conditions.
Behind the scenes, we are working closely with key stakeholders to ensure that these therapies will be accessible and affordable to all Australians needing these treatments in medically controlled environments, so that cost and geography doesn’t become a barrier.
In the last 18 months, we have assembled a comprehensive leadership team with expertise in mental illness including psychology, neuroscience and pharmacology, non-profit development, business practices and networks, public health, events, marketing and educational development.
Mind Medicine Australia is also supported by an outstanding Board, Ambassadors and an Advisory Panel of over 70 local and international experts in medicine, psychiatry, psychology, pharmacology, research, science more broadly, ethics, law, policy, anthropology, business and therapeutic practices. We have also developed a Lived Experience and Young Leaders Panel.
As we move through 2022, our vision and capacity continue to grow, as does the need to make these effective and safe therapies a legally available treatment through our medical system for the increasing number of individuals suffering as a result of the pandemic, environmental challenges and global trends which challenge social cohesiveness and social inclusion.
We ask for your continued and expanded support so that we can fund the path for psilocybin and MDMA-assisted psychotherapy to help treat the millions experiencing key mental illnesses in Australia. This is personal for every one of us.
As Carl Jung said, “The sole purpose of human existence is to kindle a light in the darkness of mere being.”
With gratitude for your interest and generosity. There has never been a more important time to support innovation in the treatment of mental illness.
Peter Hunt AM and Tania de Jong AM